Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
24
08
2018
accepted:
31
01
2019
pubmed:
9
2
2019
medline:
29
7
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-
Identifiants
pubmed: 30733269
pii: haematol.2018.205211
doi: 10.3324/haematol.2018.205211
pmc: PMC6717573
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1782-1788Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Blood. 1999 May 1;93(9):2831-8
pubmed: 10216077
N Engl J Med. 1999 Jul 1;341(1):14-21
pubmed: 10387937
Blood. 2003 Dec 1;102(12):3912-8
pubmed: 12920019
Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65
pubmed: 17317589
Blood. 2007 Nov 15;110(10):3784-92
pubmed: 17671231
Biol Blood Marrow Transplant. 2007 Nov;13(11):1304-12
pubmed: 17950917
Haematologica. 2008 Oct;93(10):1514-22
pubmed: 18728030
Blood. 2009 Dec 17;114(26):5264-70
pubmed: 19812383
Biol Blood Marrow Transplant. 2010 Mar;16(3):358-67
pubmed: 19879949
J Clin Oncol. 2010 Feb 20;28(6):1011-6
pubmed: 20065176
J Clin Oncol. 2010 Apr 10;28(11):1888-95
pubmed: 20212247
Br J Haematol. 2011 Feb;152(3):331-9
pubmed: 21133885
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
J Clin Oncol. 2011 Jun 1;29(16):2230-9
pubmed: 21464398
Blood. 2012 Mar 15;119(11):2657-64
pubmed: 22234678
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Haematologica. 2012 Oct;97(10):1574-81
pubmed: 22491742
J Clin Oncol. 2012 Oct 20;30(30):3746-51
pubmed: 23008296
Rev Bras Hematol Hemoter. 2012;34(2):109-33
pubmed: 23049402
Bone Marrow Transplant. 2013 Mar;48 Suppl 1:S1-37
pubmed: 23462821
Haematologica. 2013 Dec;98(12):1865-71
pubmed: 24038026
Exp Hematol. 2014 Feb;42(2):83-9
pubmed: 24141092
Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97
pubmed: 24161923
Blood. 2014 Aug 14;124(7):1183-91
pubmed: 24963042
Blood. 2015 May 21;125(21):3347-50; quiz 3364
pubmed: 25784679
J Hematol Oncol. 2016 Nov 8;9(1):118
pubmed: 27821187
BMC Cancer. 2016 Dec 3;16(1):933
pubmed: 27912732
Bone Marrow Transplant. 2017 Mar;52(3):372-380
pubmed: 27941763
Blood. 2017 Feb 16;129(7):832-837
pubmed: 28031182
J Hematol Oncol. 2017 Feb 22;10(1):55
pubmed: 28228106
Blood. 2017 Sep 14;130(11):1302-1314
pubmed: 28743716
Biol Blood Marrow Transplant. 2018 Feb;24(2):386-392
pubmed: 28970176
Leukemia. 2019 Mar;33(3):686-695
pubmed: 30573777